Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
Retrieved on:
Tuesday, April 11, 2023
Microtubule, Infection, University of Rochester Medical Center, Human, Partnership, University, EEV, Marketing, Public, Mpox, COVID-19, African, Animal efficacy rule, CFR, Smallpox, Research, Cmax, Cavg, Associate, Development, Patient, Multiple organ dysfunction syndrome, Dentistry, Immunology, Viral, FDA, Death, BARDA, Virus, Pneumonia, Vaccine, Microbiology, Vaccinia
MIAMI, FL, April 11, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.
Key Points:
- These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.
- The purpose of the study was to evaluate the mechanism of antiviral efficacy of sabizabulin, a novel microtubule disruptor, against the prototypical poxvirus vaccinia in cell culture.
- To assess the ability of sabizabulin to slow or stop vaccinia virus cell-to-cell spread, BSC40 cells were treated with different concentrations of sabizabulin before inoculation with vaccinia virus at a low multiplicity of infection.
- In this study, sabizabulin, by disrupting microtubules, was able to prevent the export and release of infectious vaccinia virus.